Medpace customer relationships: revenue drivers, contract posture, and who pays the bills

Medpace (NASDAQ: MEDP) is a globally‑oriented, full‑service clinical research organization that monetizes by contracting to manage and execute clinical trials across Phases I–IV and by providing related operational services and limited system access (ClinTrak). Revenue is generated almost entirely from fee‑for‑service engagements with biopharmaceutical and medical device companies, producing a sizable backlog that converts into near‑term visibility and recurring project billing. Learn more about relationship intelligence at https://nullexposure.com/.

How Medpace actually makes money and what that implies for investors

Medpace sells multi‑year and short‑term clinical services to a mix of small, mid‑sized and large sponsors, acting as the primary service provider responsible for site management, data management, monitoring, and regulatory execution. The FY2025 filing shows a material backlog—approximately $3.6 billion of performance obligations—supporting active projects, which underpins revenue visibility and cash flow conversion in the coming quarters. Medpace also provides access to its ClinTrak information system to certain customers, creating a supplementary software touchpoint embedded in service contracts.

Key operating characteristics that drive the investment thesis:

• Contracting posture: Medpace executes both short‑duration engagements and multi‑year task orders; its commercial model supports flexible contract lengths that balance project pipelines and long‑dated performance obligations (company 10‑K, FY2025).
• Counterparty concentration: The revenue mix is heavily weighted to small biopharmaceutical companies (82% of FY2025 net revenue) and mid‑sized sponsors (13%), with a smaller share from large pharmas—this shapes credit and payment risk despite diversified customer counts.
• Global delivery and complexity: Operations span North America, Europe and Asia, exposing the business to regulatory heterogeneity and regional execution risk but also to a diversified pool of sponsors and sites.
• Criticality and maturity: As a full‑service CRO, Medpace is often mission‑critical to a sponsor’s clinical timeline; that criticality increases stickiness and the probability of contract extensions once trials commence.

These characteristics create a revenue profile with high visibility from backlog and elevated client dependence on Medpace’s operational competency, while concentrating credit risk on smaller‑capitalized sponsors.

Customer relationships investors should watch

Below I cover every customer relationship disclosed in the available results and the public sources that document them.

CinRX Pharma

Medpace and CinRX have entered into several task orders under which Medpace performs clinical trial‑related services, indicating an active service relationship that is structured through project‑level task orders. According to Medpace’s FY2025 Form 10‑K, the company and CinRx have executed multiple task orders for clinical services (FY2025 10‑K).

LIB Therapeutics LLC

A master services agreement dated November 24, 2015 underpins the relationship between Medpace and LIB Therapeutics, and the parties have followed that MSA with several task orders for clinical trial services, demonstrating a multi‑year contractual framework for repeat work. This arrangement is described in Medpace’s FY2025 Form 10‑K (FY2025 10‑K).

Zelluna

Zelluna announced a clinical partnership with Medpace to support the first clinical trial of ZI‑MA4‑1, signaling a new sponsor engagement where Medpace will provide trial operations and execution support. The partnership was reported in news coverage in March 2026 (MarketScreener news items, March 10, 2026).

What these relationships reveal about business risk and runway

The three named relationships show Medpace’s core commercial pattern: an MSA or master framework paired with downstream task orders for specific trials, plus discrete new engagements announced via press channels. From an investor perspective, that structure implies:

• Revenue conversion mechanics: MSAs plus task orders deliver a cadence of billable events while the $3.6 billion backlog converts into recognized revenue under ASC 606 (company 10‑K, FY2025).
• Credit exposure concentrated in smaller sponsors: With 82% of FY2025 revenue from small biopharma and 13% from mid‑sized companies, Medpace’s receivable and collection risk is correlated to the funding cycles of its clients, increasing sensitivity to capital markets and biotech financing environments.
• Operational leverage: As a service provider with global sites, execution quality and timeline adherence determine profitability; successfully delivering for sponsors like the ones above preserves renewal and upsell potential.
• Embedded software as a stickiness tool: Supplying access to ClinTrak for customers deepens the relationship and gives Medpace an operational lock‑in point beyond pure labor and site management (company 10‑K, FY2025).

Near‑term signals to monitor

Investors and operators should track a handful of measurable signals that reflect the health of Medpace’s customer book:

• Quarterly changes in performance obligations and backlog conversion rates, which translate to short‑term revenue certainty.
• Receivables aging and bad debt provisions, given the sponsor base skew to small biopharma.
• Announcement cadence of new sponsor partnerships (like the Zelluna engagement) as an indicator of pipeline traction and market share capture.
• Renewal and expansion rates on existing MSAs and the mix between short‑term task orders and longer‑duration contracts.

Bottom line: durable revenue with a concentrated credit profile

Medpace delivers a durable, service‑led revenue stream with significant near‑term visibility from a large backlog and a global operating footprint. The core risk to NAV and earnings is counterparty credit concentration toward small biopharma sponsors and the execution complexity of global trials. Investors should balance the company’s performance obligations and service stickiness against the potential for funding‑driven delays from sponsor clients.

For deeper, transaction‑level customer mapping and ongoing relationship alerts, visit https://nullexposure.com/ to see how this intelligence maps to portfolio risk and counterparty exposure.